SWOG clinical trial number
S1106
A Randomized Phase II Trial of R-HCVAD-MTX/ARA-C Induction Followed by Consolidation With an Autologous Stem Cell Transplant vs. R-Bendamustine Induction Followed by Consolidation With an Autologous Stem Cell Transplant for Patients </= 65 Years of Age With Previously Untreated Mantle Cell Lymphoma
29% Accrual
Accrual
29%
Closed
Phase
29% Accrual
Accrual
29%
Published
Abbreviated Title
Randomized Phase II Younger Patients Mantle Cell Lymphoma
Activated
10/01/2011
Closed
06/26/2013
Participants
CTSU
Research committees
Lymphoma
Treatment
Cyclophosphamide
Dexamethasone
Vincristine
Doxorubicin
Methotrexate
Rituximab
Bendamustine
RT
Hyper-CVAD
Eligibility Criteria Expand/Collapse
Publication Information Expand/Collapse
Other Clinical Trials
S2308
SWOG Clinical Trial Number
Research Committee(s)
Lymphoma
Activated
08/01/2024
22% Accrual
Accrual
22%
Open
Phase
S2207
SWOG Clinical Trial Number
Research Committee(s)
Lymphoma
Activated
06/30/2023
12% Accrual
Accrual
12%
Open
Phase
CTSU/AHOD2131
SWOG Clinical Trial Number
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase